MitraClip: Impact of Sinus Rhythm and Heart Rate

MitraClip: Impact of Sinus Rhythm and Heart RateCourtesy of Dr. Carlos Fava.

Atrial fibrillation (AF) and fast heart rate (>70 lpm) have been shown to increase the risk of mitral valve repair surgery. The MitraClip has shown benefits in high risk patients, but its relation to abnormal heart rhythm has not yet been established.

 

760 patients were analyzed; 315 (52.4%) presented sinus rhythm (SR) and 286 (47.6%) atrial fibrillation. In the SR group, 365 patients (46.8%) presented a ≤70 lpm heart rate, and 404 (53.2%), a >70 lpm heart rate.

 

AF patients were older, had mild ventricular deterioration, and larger left auricular diameter. On the other hand, SR patients more often presented a history of MI, diabetes, (especially those with <70 heart rate), severe left ventricular function deterioration and increased end-diastolic volume.

 

Procedural success was 97.5%, with no significant differences between subgroups as regards:

  • procedural time
  • fluoroscopy
  • number of clips implanted
  • intra-procedural complications

 

There were no differences as regards in hospital stay, though SR patients presenting <70 lpm heart rate saw a shorter stay.

 

At 30 days, there were no differences in mortality (SR 3%, AF 5.8%, SR≤70 4.3% and SR>70 4.5%). The only mortality predictor was a >2 mg/dl creatinine value. Functional class saw sustained improvement across all subgroups.

 

Conclusion

These registry data (comparing a large “real world” unselected series of patients with mitral regurgitation receiving MitraClip) suggest that this intervention is safe and effective and that it reduces mitral regurgitation in most patients, regardless of baseline sinus rhythm or heart rate. While at 12 months survival rate was higher for those in SR, MACE and clinical improvement was no different between the groups.

 

Editorial Comment

This analysis of the German registry shows the MitraClip has benefits for high risk patients regardless of sinus rhythm or heart rate, as opposed to mitral valve surgery.

 

It is important to intervene before kidney failure, since this has a negative impact on results.

 

We need to evaluate these outcomes against those of larger studies.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

Original Title: Effects of atrial fibrillation and heart rateo in percutaneous mitral valve repair with MitraClip: results from the TRAnscatheter Mitral valve Intervention (TRAMI) registry.

Reference: Alexnader Jabs et al. EuroIntervention 2017;12:1697-1705.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...